Sarepta Therapeutics (SRPT) Capital Expenditures (2010 - 2026)

Sarepta Therapeutics' Capital Expenditures history runs 17 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• On a quarterly basis, Capital Expenditures fell 95.23% year-over-year to $2.1 million in Q1 2026; TTM through Mar 2026 was $60.4 million, a 59.23% decrease from a year earlier, with the FY2025 full-year figure at $102.0 million, down 25.54% from the prior year.
• Capital Expenditures slipped to $2.1 million in Q1 2026 per SRPT's latest filing, from $3.6 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $43.7 million in Q1 2025 and bottomed at $2.1 million in Q1 2026.
• The 5-year median for Capital Expenditures is $19.0 million (2023), against an average of $20.5 million.
• Across the five-year window, Capital Expenditures surged 261.02% in 2022 and tumbled 95.23% in 2026, its largest moves.
• Year by year, Capital Expenditures stood at $8.0 million in 2022, then jumped by 139.06% to $19.0 million in 2023, then jumped by 100.02% to $38.1 million in 2024, then slumped by 90.57% to $3.6 million in 2025, then sank by 42.05% to $2.1 million in 2026.
• Per Business Quant, the three latest SRPT Capital Expenditures figures stand at $2.1 million (Q1 2026), $3.6 million (Q4 2025), and $22.9 million (Q3 2025).